Viking Therapeutics (VKTX) Change in Acquisitions & Divestments (2015 - 2026)

Viking Therapeutics has disclosed Change in Acquisitions & Divestments across 12 years of filings, most recently posting $126.6 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $126.6 million, down 57.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $590.2 million (down 17.92% YoY), and the FY2025 annual result was $759.4 million, up 35.61% from the prior year.
• Change in Acquisitions & Divestments came in at $126.6 million for Q1 2026 at Viking Therapeutics, up from $116.1 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $295.9 million in Q1 2025 to a low of $32.3 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $116.1 million (2025), against an average of $113.0 million.
• Across the five-year window, Change in Acquisitions & Divestments jumped 163.05% in 2024 and slumped 57.2% in 2026, its largest moves.
• Viking Therapeutics' Change in Acquisitions & Divestments stood at $51.9 million in 2022, then jumped by 156.94% to $133.3 million in 2023, then climbed by 7.71% to $143.5 million in 2024, then decreased by 19.12% to $116.1 million in 2025, then advanced by 9.06% to $126.6 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $126.6 million (Q1 2026), $116.1 million (Q4 2025), and $181.5 million (Q3 2025), per Business Quant data.